RegCell, Inc.
RegCell is developing cell therapies for autoimmune disease by epigenetically reprogramming pathogenic conventional T cells into stable regulatory T cells, aiming to restore immune tolerance without gene engineering; its platform is advancing toward clinical development.
$44MSeries A
Participant